Assignee
PROTEOSTASIS THERAPEUTICS INC
US·23 granted patents·19 pending applications·103 citations·filing 2006–2025
Top patents by PatentIndex Score
42 records- 0197US9745292B2Compounds, compositions, and methods for increasing CFTR activityPROTEOSTASIS THERAPEUTICS INC·Filed 2015·Granted Aug 29, 2017·14 cites·26 claims
- 0296US10017503B2Compounds, compositions, and methods for increasing CFTR activityPROTEOSTASIS THERAPEUTICS INC·Filed 2017·Granted Jul 10, 2018·11 cites·28 claims
- 0396US9790219B2Compounds, compositions, and methods for increasing CFTR activityPROTEOSTASIS THERAPEUTICS INC·Filed 2015·Granted Oct 17, 2017·16 cites·38 claims
- 0494US10548878B2Compounds, compositions, and methods of increasing CFTR activityPROTEOSTASIS THERAPEUTICS INC·Filed 2016·Granted Feb 4, 2020·8 cites·23 claims
- 0593US10550106B2Compounds, compositions, and methods for modulating CFTRPROTEOSTASIS THERAPEUTICS INC·Filed 2016·Granted Feb 4, 2020·9 cites·13 claims
- 0692US2026078136A1Compounds, compositions, and methods for modulating cftrPROTEOSTASIS THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 0791US9850262B2Proteasome activity enhancing compoundsPROTEOSTASIS THERAPEUTICS INC·Filed 2016·Granted Dec 26, 2017·6 cites·25 claims
- 0890US11242361B2Proteasome activity enhancing compoundsPROTEOSTASIS THERAPEUTICS INC·Filed 2020·Granted Feb 8, 2022·2 cites·34 claims
- 0990US10174014B2Compounds, compositions, and methods for increasing CFTR activityPROTEOSTASIS THERAPEUTICS INC·Filed 2015·Granted Jan 8, 2019·9 cites·25 claims
- 1088US2024109922A1Compounds, compositions, and methods for modulating cftrPROTEOSTASIS THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1187US10662207B2Compounds, compositions, and methods for modulating CFTRPROTEOSTASIS THERAPEUTICS INC·Filed 2017·Granted May 26, 2020·4 cites·27 claims
- 1287US10392378B2Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosisPROTEOSTASIS THERAPEUTICS INC·Filed 2015·Granted Aug 27, 2019·7 cites·8 claims
- 1387US10392372B2Compounds, compositions, and methods for increasing CFTR activityPROTEOSTASIS THERAPEUTICS INC·Filed 2015·Granted Aug 27, 2019·6 cites·11 claims
- 1487US2024368198A1Compounds, compositions, and methods for modulating cftrPROTEOSTASIS THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1586US10344023B2Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosisPROTEOSTASIS THERAPEUTICS INC·Filed 2015·Granted Jul 9, 2019·6 cites·20 claims
- 1684US11746098B2Proteasome activity enhancing compoundsPROTEOSTASIS THERAPEUTICS INC·Filed 2020·Granted Sep 5, 2023·1 cites·25 claims
- 1780US2024139158A1Methods of treating pulmonary diseases and disordersPROTEOSTASIS THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1879US10738040B2Compounds, compositions, and methods for increasing CFTR activityPROTEOSTASIS THERAPEUTICS INC·Filed 2018·Granted Aug 11, 2020·1 cites·23 claims
- 1976US11136313B2Compounds, compositions, and methods for modulating CFTRPROTEOSTASIS THERAPEUTICS INC·Filed 2019·Granted Oct 5, 2021·1 cites·24 claims
- 2076US10738011B2Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosisPROTEOSTASIS THERAPEUTICS INC·Filed 2015·Granted Aug 11, 2020·1 cites·4 claims
- 2175US10899751B2Compounds, compositions, and methods for increasing CFTR activityPROTEOSTASIS THERAPEUTICS INC·Filed 2017·Granted Jan 26, 2021·1 cites·17 claims
- 2272US11248010B2Compounds, compositions, and methods for modulating CFTRPROTEOSTASIS THERAPEUTICS INC·Filed 2020·Granted Feb 15, 2022·0 cites·11 claims
- 2369US11098035B2Compounds, compositions, and methods for increasing CFTR activityPROTEOSTASIS THERAPEUTICS INC·Filed 2019·Granted Aug 24, 2021·0 cites·2 claims
- 2469US2022175735A1Methods of treating pulmonary diseases and disordersPROTEOSTASIS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2567US2022227739A1Compounds, compositions, and methods for modulating cftrPROTEOSTASIS THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2664US2018282352A1Proteasome activity enhancing compoundsPROTEOSTASIS THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2763US11560385B2Proteasome activity enhancing compoundsPROTEOSTASIS THERAPEUTICS INC·Filed 2020·Granted Jan 24, 2023·0 cites·21 claims
- 2861US11083709B2Compounds, compositions, and methods of increasing CFTR activityPROTEOSTASIS THERAPEUTICS INC·Filed 2019·Granted Aug 10, 2021·0 cites·11 claims
- 2961US2018369209A1Methods of treating pulmonary diseases and disordersPROTEOSTASIS THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3055US10532996B2Proteostasis regulatorsPROTEOSTASIS THERAPEUTICS INC·Filed 2017·Granted Jan 14, 2020·0 cites·5 claims
- 3154US2018147187A1Compounds, compositions, and methods for increasing cftr activityPROTEOSTASIS THERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 3250US2021369749A1Compounds, compositions, and methods for increasing cftr activityPROTEOSTASIS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3347US2020340984A1Methods of quantifying cftr protein expressionPROTEOSTASIS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3445US9399647B2Proteasome activity modulating compoundsPROTEOSTASIS THERAPEUTICS INC·Filed 2014·Granted Jul 26, 2016·0 cites·11 claims
- 3545US2016151335A1Methods of modulating cftr activityPROTEOSTASIS THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 3644US2015166567A1Proteasome activity enhancing compoundsPROTEOSTASIS THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 3742US2019248779A1Compounds, compositions, and methods for increasing cftr activityPROTEOSTASIS THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3841US2020055844A14-sulfonylaminocarbonylquinoline derivatives for increasing cftr activityPROTEOSTASIS THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3940US2019256474A1N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosisPROTEOSTASIS THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4040US2019248765A1Compounds, compositions, and methods for increasing cftr activityPROTEOSTASIS THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4140US2019154661A1Methods of identifying cftr modulatorsPROTEOSTASIS THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4239US2019022071A1Methods of treating pulmonary diseases and disordersPROTEOSTASIS THERAPEUTICS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when PROTEOSTASIS THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →